{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T03:56:32Z","timestamp":1794455792111,"version":"4.9.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T00:00:00Z","timestamp":1683763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T00:00:00Z","timestamp":1683763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000049","name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging","doi-asserted-by":"publisher","award":["R01-AG077573"],"award-info":[{"award-number":["R01-AG077573"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Parkinson\u2019s disease (PD) and dementia with Lewy bodies (DLB) are progressive neurodegenerative diseases characterized by the accumulation of misfolded \u03b1-synuclein in the form of Lewy pathology. While most cases are sporadic, there are rare genetic mutations that cause disease and more common variants that increase incidence of disease. The most prominent genetic mutations for PD and DLB are in the\n                    <jats:italic>GBA1<\/jats:italic>\n                    and\n                    <jats:italic>LRRK2<\/jats:italic>\n                    genes.\n                    <jats:italic>GBA1<\/jats:italic>\n                    mutations are associated with decreased glucocerebrosidase activity and lysosomal accumulation of its lipid substrates, glucosylceramide and glucosylsphingosine. Previous studies have shown a link between this enzyme and lipids even in sporadic PD. However, it is unclear how the protein pathologies of disease are related to enzyme activity and glycosphingolipid levels. To address this gap in knowledge, we examined quantitative protein pathology, glucocerebrosidase activity and lipid substrates in parallel from 4 regions of 91 brains with no neurological disease, idiopathic,\n                    <jats:italic>GBA1<\/jats:italic>\n                    -linked, or\n                    <jats:italic>LRRK2<\/jats:italic>\n                    -linked PD and DLB. We find that several biomarkers are altered with respect to mutation and progression to dementia. We found mild association of glucocerebrosidase activity with disease, but a strong association of glucosylsphingosine with \u03b1-synuclein pathology, irrespective of genetic mutation. This association suggests that Lewy pathology precipitates changes in lipid levels related to progression to dementia.\n                  <\/jats:p>","DOI":"10.1038\/s41531-023-00517-w","type":"journal-article","created":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T15:02:54Z","timestamp":1683817374000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Glucocerebrosidase activity and lipid levels are related to protein pathologies in Parkinson\u2019s disease"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5513-7758","authenticated-orcid":false,"given":"Cheryl E. G.","family":"Leyns","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Prigent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenna","family":"Beezhold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihang","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan G.","family":"Hatcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peining","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"EunRan","family":"Suh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7400-9097","authenticated-orcid":false,"given":"Vivianna M.","family":"Van Deerlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9239-8794","authenticated-orcid":false,"given":"John Q.","family":"Trojanowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3536-6902","authenticated-orcid":false,"given":"Virginia M. Y.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew E.","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Fell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9710-0726","authenticated-orcid":false,"given":"Michael X.","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,11]]},"reference":[{"key":"517_CR1","doi-asserted-by":"publisher","first-page":"134316","DOI":"10.1016\/j.neulet.2019.134316","volume":"709","author":"MX Henderson","year":"2019","unstructured":"Henderson, M. X., Trojanowski, J. Q. & Lee, V. M. alpha-Synuclein pathology in Parkinson\u2019s disease and related alpha-synucleinopathies. Neurosci. Lett. 709, 134316 (2019).","journal-title":"Neurosci. Lett."},{"key":"517_CR2","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1001\/archneur.60.3.387","volume":"60","author":"D Aarsland","year":"2003","unstructured":"Aarsland, D., Andersen, K., Larsen, J. P., Lolk, A. & Kragh-Sorensen, P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch. Neurol. 60, 387\u2013392 (2003).","journal-title":"Arch. Neurol."},{"key":"517_CR3","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S1474-4422(16)30291-5","volume":"16","author":"DJ Irwin","year":"2017","unstructured":"Irwin, D. J. et al. Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis. Lancet Neurol. 16, 55\u201365 (2017).","journal-title":"Lancet Neurol."},{"key":"517_CR4","doi-asserted-by":"publisher","first-page":"S221","DOI":"10.1016\/S1353-8020(08)70005-1","volume":"13","author":"Y Tsuboi","year":"2007","unstructured":"Tsuboi, Y., Uchikado, H. & Dickson, D. W. Neuropathology of Parkinson\u2019s disease dementia and dementia with Lewy bodies with reference to striatal pathology. Parkin. Relat. Disord. 13, S221\u2013S224 (2007).","journal-title":"Parkin. Relat. Disord."},{"key":"517_CR5","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1002\/mds.26796","volume":"31","author":"RB Postuma","year":"2016","unstructured":"Postuma, R. B. et al. Abolishing the 1-year rule: How much evidence will be enough? Mov. Disord.: Off. J. Mov. Disord. Soc. 31, 1623\u20131627 (2016).","journal-title":"Mov. Disord.: Off. J. Mov. Disord. Soc."},{"key":"517_CR6","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1586\/ern.12.131","volume":"12","author":"KA Jellinger","year":"2012","unstructured":"Jellinger, K. A. Neurobiology of cognitive impairment in Parkinson\u2019s disease. Expert Rev. Neurother. 12, 1451\u20131466 (2012).","journal-title":"Expert Rev. Neurother."},{"key":"517_CR7","doi-asserted-by":"publisher","first-page":"104876","DOI":"10.1016\/j.nbd.2020.104876","volume":"141","author":"HA Lashuel","year":"2020","unstructured":"Lashuel, H. A. Do Lewy bodies contain alpha-synuclein fibrils? and Does it matter? A brief history and critical analysis of recent reports. Neurobiol. Dis. 141, 104876 (2020).","journal-title":"Neurobiol. Dis."},{"key":"517_CR8","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1016\/S0140-6736(21)00218-X","volume":"397","author":"BR Bloem","year":"2021","unstructured":"Bloem, B. R., Okun, M. S. & Klein, C. Parkinson\u2019s disease. Lancet 397, 2284\u20132303 (2021).","journal-title":"Lancet"},{"key":"517_CR9","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1038\/ng.3043","volume":"46","author":"MA Nalls","year":"2014","unstructured":"Nalls, M. A. et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson\u2019s disease. Nat. Genet. 46, 989\u2013993 (2014).","journal-title":"Nat. Genet."},{"key":"517_CR10","doi-asserted-by":"publisher","first-page":"e115747","DOI":"10.1371\/journal.pone.0115747","volume":"9","author":"J Chen","year":"2014","unstructured":"Chen, J. et al. Glucocerebrosidase gene mutations associated with Parkinson\u2019s disease: a meta-analysis in a Chinese population. PloS ONE 9, e115747 (2014).","journal-title":"PloS ONE"},{"key":"517_CR11","doi-asserted-by":"publisher","unstructured":"Vieira, S. R. L. & Schapira, A. H. V. Glucocerebrosidase mutations and Parkinson disease. J. Neural Transm. (Vienna), https:\/\/doi.org\/10.1007\/s00702-022-02531-3 (2022).","DOI":"10.1007\/s00702-022-02531-3"},{"key":"517_CR12","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1615\/CritRevOncog.2013006060","volume":"18","author":"BE Rosenbloom","year":"2013","unstructured":"Rosenbloom, B. E. & Weinreb, N. J. Gaucher disease: a comprehensive review. Crit. Rev. Oncog. 18, 163\u2013175 (2013).","journal-title":"Crit. Rev. Oncog."},{"key":"517_CR13","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","volume":"361","author":"E Sidransky","year":"2009","unstructured":"Sidransky, E. et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson\u2019s disease. N. Engl. J. Med. 361, 1651\u20131661 (2009).","journal-title":"N. Engl. J. Med."},{"key":"517_CR14","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1001\/jamaneurol.2013.1925","volume":"70","author":"MA Nalls","year":"2013","unstructured":"Nalls, M. A. et al. A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. JAMA Neurol. 70, 727\u2013735 (2013).","journal-title":"JAMA Neurol."},{"key":"517_CR15","doi-asserted-by":"publisher","unstructured":"Smith, L. & Schapira, A. H. V. GBA Variants and Parkinson Disease: Mechanisms and Treatments. Cells 11, https:\/\/doi.org\/10.3390\/cells11081261 (2022).","DOI":"10.3390\/cells11081261"},{"key":"517_CR16","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/ana.23614","volume":"72","author":"ME Gegg","year":"2012","unstructured":"Gegg, M. E. et al. Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains. Ann. Neurol. 72, 455\u2013463 (2012).","journal-title":"Ann. Neurol."},{"key":"517_CR17","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1002\/acn3.177","volume":"2","author":"EM Rocha","year":"2015","unstructured":"Rocha, E. M. et al. Progressive decline of glucocerebrosidase in aging and Parkinson\u2019s disease. Ann. Clin. Transl. Neurol. 2, 433\u2013438 (2015).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"517_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-019-0339-z","volume":"14","author":"M Huebecker","year":"2019","unstructured":"Huebecker, M. et al. Reduced sphingolipid hydrolase activities, substrate accumulation and ganglioside decline in Parkinson\u2019s disease. Mol. Neurodegen. 14, 40 (2019).","journal-title":"Mol. Neurodegen."},{"key":"517_CR19","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.nbd.2018.09.015","volume":"121","author":"AL Gundner","year":"2019","unstructured":"Gundner, A. L. et al. Path mediation analysis reveals GBA impacts Lewy body disease status by increasing alpha-synuclein levels. Neurobiol. Dis. 121, 205\u2013213 (2019).","journal-title":"Neurobiol. Dis."},{"key":"517_CR20","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.cell.2011.06.001","volume":"146","author":"JR Mazzulli","year":"2011","unstructured":"Mazzulli, J. R. et al. Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 146, 37\u201352 (2011).","journal-title":"Cell"},{"key":"517_CR21","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.neuron.2019.12.004","volume":"105","author":"MX Henderson","year":"2020","unstructured":"Henderson, M. X. et al. Glucocerebrosidase Activity Modulates Neuronal Susceptibility to Pathological alpha-Synuclein Insult. Neuron 105, 822\u2013836.e827 (2020).","journal-title":"Neuron"},{"key":"517_CR22","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.neuron.2017.01.018","volume":"93","author":"E Aflaki","year":"2017","unstructured":"Aflaki, E., Westbroek, W. & Sidransky, E. The Complicated Relationship between Gaucher Disease and Parkinsonism: Insights from a Rare Disease. Neuron 93, 737\u2013746 (2017).","journal-title":"Neuron"},{"key":"517_CR23","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1093\/brain\/awt367","volume":"137","author":"KE Murphy","year":"2014","unstructured":"Murphy, K. E. et al. Reduced glucocerebrosidase is associated with increased alpha-synuclein in sporadic Parkinson\u2019s disease. Brain: J. Neurol. 137, 834\u2013848 (2014).","journal-title":"Brain: J. Neurol."},{"key":"517_CR24","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1002\/mds.26278","volume":"30","author":"ME Gegg","year":"2015","unstructured":"Gegg, M. E. et al. No evidence for substrate accumulation in Parkinson brains with GBA mutations. Mov. Disord.: Off. J. Mov. Disord. Soc. 30, 1085\u20131089 (2015).","journal-title":"Mov. Disord.: Off. J. Mov. Disord. Soc."},{"key":"517_CR25","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1021\/acs.analchem.5b04227","volume":"88","author":"M Boutin","year":"2016","unstructured":"Boutin, M., Sun, Y., Shacka, J. J. & Auray-Blais, C. Tandem Mass Spectrometry Multiplex Analysis of Glucosylceramide and Galactosylceramide Isoforms in Brain Tissues at Different Stages of Parkinson Disease. Anal. Chem. 88, 1856\u20131863 (2016).","journal-title":"Anal. Chem."},{"key":"517_CR26","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s00401-021-02367-3","volume":"142","author":"M Kurzawa-Akanbi","year":"2021","unstructured":"Kurzawa-Akanbi, M. et al. Altered ceramide metabolism is a feature in the extracellular vesicle-mediated spread of alpha-synuclein in Lewy body disorders. Acta Neuropatholog. 142, 961\u2013984 (2021).","journal-title":"Acta Neuropatholog."},{"key":"517_CR27","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41531-022-00363-2","volume":"8","author":"S Blumenreich","year":"2022","unstructured":"Blumenreich, S. et al. Elevation of gangliosides in four brain regions from Parkinson\u2019s disease patients with a GBA mutation. NPJ Parkinson\u2019s Dis. 8, 99 (2022).","journal-title":"NPJ Parkinson\u2019s Dis."},{"key":"517_CR28","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S1474-4422(08)70117-0","volume":"7","author":"DG Healy","year":"2008","unstructured":"Healy, D. G. et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson\u2019s disease: a case-control study. Lancet Neurol. 7, 583\u2013590 (2008).","journal-title":"Lancet Neurol."},{"key":"517_CR29","doi-asserted-by":"publisher","first-page":"498","DOI":"10.3389\/fnins.2020.00498","volume":"14","author":"M Madureira","year":"2020","unstructured":"Madureira, M., Connor-Robson, N. & Wade-Martins, R. \u201cLRRK2: Autophagy and Lysosomal Activity\u201d. Front. Neurosci. 14, 498 (2020).","journal-title":"Front. Neurosci."},{"key":"517_CR30","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1042\/BST20201146","volume":"49","author":"G Piccoli","year":"2021","unstructured":"Piccoli, G. & Volta, M. LRRK2 along the Golgi and lysosome connection: a jamming situation. Biochem Soc. Trans. 49, 2063\u20132072 (2021).","journal-title":"Biochem Soc. Trans."},{"key":"517_CR31","doi-asserted-by":"publisher","first-page":"2648","DOI":"10.1093\/brain\/awv179","volume":"138","author":"RN Alcalay","year":"2015","unstructured":"Alcalay, R. N. et al. Glucocerebrosidase activity in Parkinson\u2019s disease with and without GBA mutations. Brain: J. Neurol. 138, 2648\u20132658 (2015).","journal-title":"Brain: J. Neurol."},{"key":"517_CR32","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41531-022-00354-3","volume":"8","author":"M Kedariti","year":"2022","unstructured":"Kedariti, M. et al. LRRK2 kinase activity regulates GCase level and enzymatic activity differently depending on cell type in Parkinson\u2019s disease. NPJ Parkinson\u2019s Dis. 8, 92 (2022).","journal-title":"NPJ Parkinson\u2019s Dis."},{"key":"517_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13413-w","volume":"10","author":"D Ysselstein","year":"2019","unstructured":"Ysselstein, D. et al. LRRK2 kinase activity regulates lysosomal glucocerebrosidase in neurons derived from Parkinson\u2019s disease patients. Nat. Commun. 10, 5570 (2019).","journal-title":"Nat. Commun."},{"key":"517_CR34","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1093\/glycob\/cwab046","volume":"31","author":"S Reza","year":"2021","unstructured":"Reza, S., Ugorski, M. & Suchanski, J. Glucosylceramide and galactosylceramide, small glycosphingolipids with significant impact on health and disease. Glycobiology 31, 1416\u20131434 (2021).","journal-title":"Glycobiology"},{"key":"517_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-019-0836-x","volume":"7","author":"MX Henderson","year":"2019","unstructured":"Henderson, M. X., Sengupta, M., Trojanowski, J. Q. & Lee, V. M. Y. Alzheimer\u2019s disease tau is a prominent pathology in LRRK2 Parkinson\u2019s disease. Acta Neuropathol. Commun. 7, 183 (2019).","journal-title":"Acta Neuropathol. Commun."},{"key":"517_CR36","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1001\/jamaneurol.2014.313","volume":"71","author":"RN Alcalay","year":"2014","unstructured":"Alcalay, R. N. et al. Comparison of Parkinson risk in Ashkenazi Jewish patients with Gaucher disease and GBA heterozygotes. JAMA Neurol. 71, 752\u2013757 (2014).","journal-title":"JAMA Neurol."},{"key":"517_CR37","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1212\/WNL.0b013e318245f476","volume":"78","author":"M Anheim","year":"2012","unstructured":"Anheim, M. et al. Penetrance of Parkinson disease in glucocerebrosidase gene mutation carriers. Neurology 78, 417\u2013420 (2012).","journal-title":"Neurology"},{"key":"517_CR38","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.bbrc.2016.08.082","volume":"478","author":"R Ferrazza","year":"2016","unstructured":"Ferrazza, R. et al. LRRK2 deficiency impacts ceramide metabolism in brain. Biochem. Biophys. Res. Commun. 478, 1141\u20131146 (2016).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"517_CR39","doi-asserted-by":"publisher","first-page":"892899","DOI":"10.3389\/fncel.2022.892899","volume":"16","author":"RL Wallings","year":"2022","unstructured":"Wallings, R. L. et al. WHOPPA Enables Parallel Assessment of Leucine-Rich Repeat Kinase 2 and Glucocerebrosidase Enzymatic Activity in Parkinson\u2019s Disease Monocytes. Front. Cell. Neurosci. 16, 892899 (2022).","journal-title":"Front. Cell. Neurosci."},{"key":"517_CR40","doi-asserted-by":"publisher","first-page":"9617","DOI":"10.1523\/JNEUROSCI.1525-17.2017","volume":"37","author":"YV Taguchi","year":"2017","unstructured":"Taguchi, Y. V. et al. Glucosylsphingosine Promotes alpha-Synuclein Pathology in Mutant GBA-Associated Parkinson\u2019s Disease. J. Neurosci. 37, 9617\u20139631 (2017).","journal-title":"J. Neurosci."},{"key":"517_CR41","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41531-021-00241-3","volume":"7","author":"YE Huh","year":"2021","unstructured":"Huh, Y. E. et al. Glucosylceramide in cerebrospinal fluid of patients with GBA-associated and idiopathic Parkinson\u2019s disease enrolled in PPMI. NPJ Parkinson\u2019s Dis. 7, 102 (2021).","journal-title":"NPJ Parkinson\u2019s Dis."},{"key":"517_CR42","doi-asserted-by":"publisher","first-page":"557","DOI":"10.3233\/JPD-212714","volume":"12","author":"MJ Peterschmitt","year":"2022","unstructured":"Peterschmitt, M. J. et al. Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson\u2019s Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOVES-PD Trial. J. Parkinson\u2019s Dis. 12, 557\u2013570 (2022).","journal-title":"J. Parkinson\u2019s Dis."},{"key":"517_CR43","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1007\/s00401-003-0766-2","volume":"106","author":"K Imamura","year":"2003","unstructured":"Imamura, K. et al. Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson\u2019s disease brains. Acta Neuropathol. 106, 518\u2013526 (2003).","journal-title":"Acta Neuropathol."},{"key":"517_CR44","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1212\/WNL.38.8.1285","volume":"38","author":"PL McGeer","year":"1988","unstructured":"McGeer, P. L., Itagaki, S., Boyes, B. E. & McGeer, E. G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson\u2019s and Alzheimer\u2019s disease brains. Neurology 38, 1285\u20131291 (1988).","journal-title":"Neurology"},{"key":"517_CR45","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00401-017-1679-9","volume":"134","author":"EB Lee","year":"2017","unstructured":"Lee, E. B. et al. Expansion of the classification of FTLD-TDP: distinct pathology associated with rapidly progressive frontotemporal degeneration. Acta Neuropathol. 134, 65\u201378 (2017).","journal-title":"Acta Neuropathol."},{"key":"517_CR46","doi-asserted-by":"publisher","first-page":"104626","DOI":"10.1016\/j.nbd.2019.104626","volume":"134","author":"EM Rocha","year":"2020","unstructured":"Rocha, E. M. et al. LRRK2 inhibition prevents endolysosomal deficits seen in human Parkinson\u2019s disease. Neurobiol. Dis. 134, 104626 (2020).","journal-title":"Neurobiol. Dis."},{"key":"517_CR47","doi-asserted-by":"publisher","first-page":"8288","DOI":"10.1021\/acs.analchem.7b01442","volume":"89","author":"R Hamler","year":"2017","unstructured":"Hamler, R. et al. Glucosylceramide and Glucosylsphingosine Quantitation by Liquid Chromatography-Tandem Mass Spectrometry to Enable In Vivo Preclinical Studies of Neuronopathic Gaucher Disease. Anal. Chem. 89, 8288\u20138295 (2017).","journal-title":"Anal. Chem."},{"key":"517_CR48","doi-asserted-by":"publisher","unstructured":"Breiman, L. Classification and Regression Trees (1st ed.). Routledge, https:\/\/doi.org\/10.1201\/9781315139470 (1984).","DOI":"10.1201\/9781315139470"},{"key":"517_CR49","unstructured":"Therneau, T. A., B; Ripley, B. rpart: Recursive Partitioning and Regression Trees. R package 4.1.16, https:\/\/CRAN.R-project.org\/package=rpart (2022)."},{"key":"517_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v028.i05","volume":"28","author":"M Kuhn","year":"2008","unstructured":"Kuhn, M. Building Predictive Models in R Using the caret Package. J. Stat. Softw. 28, 1\u201326 (2008).","journal-title":"J. Stat. Softw."},{"key":"517_CR51","unstructured":"R: A Language and Environment for Statistical Computing (2018)."},{"key":"517_CR52","doi-asserted-by":"publisher","unstructured":"Patil, I. Visualization with statistical details: The \u2018ggstatsplot\u2019 approach. Journal of Open Source Software 6, https:\/\/doi.org\/10.21105\/joss.03167 (2021).","DOI":"10.21105\/joss.03167"}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-023-00517-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-023-00517-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-023-00517-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T16:02:23Z","timestamp":1683820943000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-023-00517-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,11]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["517"],"URL":"https:\/\/doi.org\/10.1038\/s41531-023-00517-w","relation":{},"ISSN":["2373-8057"],"issn-type":[{"value":"2373-8057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,11]]},"assertion":[{"value":"25 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing non-financial interests but the following competing financial interests: C.E.G.L., L.Y., N.H., P.T., J.K., M.F., and M.K. are salaried employees of Merck & Co., Inc.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"74"}}